Israeli Startup StimCardio Raises $30M for Atrial Fibrillation Wristband
Israeli startup StimCardio raises $30 million for a non-invasive atrial fibrillation treatment wristband, while Ichilov Hospital partners with AI firm Wonderful.
Israeli medical device startup StimCardio has secured $30 million in a funding round to advance its non-invasive wristband designed to treat atrial fibrillation through targeted nerve stimulation.
Atrial fibrillation affects roughly 59 million people globally. Current treatments primarily rely on pharmacological interventions or ablation procedures, which involve burning small areas of heart tissue. According to Amos Ziv, the company's scientific co-founder, clinical trials demonstrated that the device reduced symptoms such as shortness of breath, palpitations, and fatigue by approximately 80% in primary patients while decreasing atrial fibrillation burden. Among patients who previously underwent unsuccessful ablation, the device lowered recurrence rates by 50% compared to a control group.
The financing round was led by Metis Medtech, a fund founded by serial medtech entrepreneur John Slump, with participation from Catalyst Health Ventures and strategic medical device corporations. StimCardio plans to enter a pivotal multi-center clinical trial before seeking De Novo clearance from the U.S. Food and Drug Administration (FDA).
In other technology news, the Tel Aviv Sourasky Medical Center (Ichilov Hospital) has announced a strategic partnership with enterprise artificial intelligence firm Wonderful. The AI company, which recently raised $550 million at a $5.0 billion valuation, will provide its operating system to integrate AI agents into Ichilov's clinical, operational, and service workflows, serving as a global model for healthcare innovation.
